Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more
Xvivo Perfusion AB (publ) (XVIPF) - Total Assets
Latest total assets as of December 2025: $2.37 Billion USD
Based on the latest financial reports, Xvivo Perfusion AB (publ) (XVIPF) holds total assets worth $2.37 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xvivo Perfusion AB (publ) - Total Assets Trend (2012–2025)
This chart illustrates how Xvivo Perfusion AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Xvivo Perfusion AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
Xvivo Perfusion AB (publ)'s total assets of $2.37 Billion consist of 29.0% current assets and 71.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.3% |
| Accounts Receivable | $147.29 Million | 6.2% |
| Inventory | $247.83 Million | 10.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $838.18 Million | 35.4% |
| Goodwill | $608.53 Million | 25.7% |
Asset Composition Trend (2012–2025)
This chart illustrates how Xvivo Perfusion AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xvivo Perfusion AB (publ)'s current assets represent 29.0% of total assets in 2025, an increase from 28.2% in 2012.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2025, up from 6.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, a decrease from 68.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 35.4% of total assets.
Xvivo Perfusion AB (publ) Competitors by Total Assets
Key competitors of Xvivo Perfusion AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Xvivo Perfusion AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Xvivo Perfusion AB (publ) generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Xvivo Perfusion AB (publ) generates $ 1.06 in net profit.
Xvivo Perfusion AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.77 | 4.58 | 6.15 |
| Quick Ratio | 3.68 | 3.30 | 5.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $567.41 Million | $ 635.57 Million | $ 389.82 Million |
Xvivo Perfusion AB (publ) - Advanced Valuation Insights
This section examines the relationship between Xvivo Perfusion AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | $2.37 Billion |
| Market Capitalization | $607.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xvivo Perfusion AB (publ)'s assets below their book value (0.26 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Xvivo Perfusion AB (publ)'s assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Xvivo Perfusion AB (publ) (2012–2025)
The table below shows the annual total assets of Xvivo Perfusion AB (publ) from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.37 Billion | -1.44% |
| 2024-12-31 | $2.40 Billion | +9.43% |
| 2023-12-31 | $2.20 Billion | +26.69% |
| 2022-12-31 | $1.73 Billion | +12.35% |
| 2021-12-31 | $1.54 Billion | +34.10% |
| 2020-12-31 | $1.15 Billion | +81.30% |
| 2019-12-31 | $634.49 Million | +8.16% |
| 2018-12-31 | $586.61 Million | +8.93% |
| 2017-12-31 | $538.54 Million | +54.18% |
| 2016-12-31 | $349.30 Million | +71.07% |
| 2015-12-31 | $204.18 Million | +1.23% |
| 2014-12-31 | $201.70 Million | +58.12% |
| 2013-12-31 | $127.56 Million | +11.39% |
| 2012-12-31 | $114.52 Million | -- |